Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
1
17%
Ph phase_3
3
50%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 33 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

NCT00048113
completedphase_2

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

NCT00063414
completedphase_2

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

NCT00063830
completedphase_3

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

NCT00048295
completedphase_3

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

NCT02525523
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00048113Phase 3

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Completed
NCT00063414Phase 2

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Completed
NCT00063830Phase 2

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

Completed
NCT00048295Phase 3

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Completed
NCT02525523Phase 3

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Completed
NCT03473626Phase 1

Phase 1 Food Effect Study for Alicaforsen Tablets

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6